Treatment of autoimmune hepatitis

Seminars in Liver Disease

Volumn 29, Issue 3, 2009, Pages 273-285

  Strassburg, Christian P ^a   Manns, Michael P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Budesonide; Corticosteroids; First pass effect; Immunosuppression; Transplantation

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEFLAZACORT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; URSODEOXYCHOLIC ACID;

ABDOMINAL DISCOMFORT; ACNE; ARTHRALGIA; AUTOIMMUNE HEPATITIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CARCINOGENICITY; CATARACT; CLINICAL TRIAL; DIABETES MELLITUS; DORSAL HUMP; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; GRAFT FAILURE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LIVER CIRRHOSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; LYMPHOCYTOPENIA; MOON FACE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEPHROTOXICITY; OBESITY; PRIORITY JOURNAL; PROGNOSIS; RASH; RECURRENT DISEASE; REMISSION; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; STRIAE RUBRAE; TERATOGENICITY; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN;

ADULT; AGE FACTORS; AGED; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GRAFT SURVIVAL; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 68849092540     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0029-1233534     Document Type: Review

References (90)

1. Waldenström J. Leber, Blutproteine und Nahrungseiweisse. Dtsch Gesellsch Verd Stoffw 1950;15:113-119
2. Cowling I, Mackay IR, Taft LI. Lupoid hepatitis. Lancet 1956;271:1323-1326
3. Strassburg CP, Obermayer-Straub P, Manns MP. Autoimmunity in liver diseases. Clin Rev Allergy Immunol 2000; 18(2):127-139
4. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31(5): 929-938
5. Hennes EM, Zeniya M, Czaja AJ, et al; International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48(1): 169-176
6. Strassburg CP, Manns MP. Autoantibodies and autoantigens in autoimmune hepatitis. Semin Liver Dis 2002;22(4):339-352
7. Johnson PJ, McFarlane IG. Meeting report: International autoimmune hepatitis group. Hepatology 1993;18(4):998-1005
8. Strassburg CP, Manns MP. Autoimmune hepatitis in the elderly: what is the difference? J Hepatol 2006;45(4):480-482
9. Strassburg CP, Manns MP. Autoimmune hepatitis versus viral hepatitis C. Liver 1995;15(5):225-232
10. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991;88(4):1370-1378
11. Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest 1989;83(3):1066-1072
12. Strassburg CP, Obermayer-Straub P, Alex B, et al. Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. Gastroenterology 1996; 111(6):1576-1586
13. Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Büschenfelde KH. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987;1(8528):292-294
14. Stechemesser E, Klein R, Berg PA. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology 1993;18(1):1-9
15. Gelpi CSE, Sontheimer EJ, Rodriguez-Sanchez JL. Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci U S A 1992;89(20):9739-9743
16. Volkmann M, Martin L, Bäurle A, et al. Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis. Hepatology 2001;33(3):591-596
17. Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis [see comment]. Lancet 2000;355(9214):1510-1515
18. Dienes HP, Popper H, Manns M, et al. Histologic features in autoimmune hepatitis. Z Gastroenterol 1989;27:325-330
19. Nishioka M, Morshed SA, Kono K, et al. Frequency and significance of antibodies to P450IID6 protein in Japanese patients with chronic hepatitis C. J Hepatol 1997;26(5):992-1000
20. Nishioka M, Morshed SA, McFarlane IG. Geographical Variation in the Frequency and Characteristics of Autoimmune Liver Diseases. Amsterdam: Elsevier; 1998:413-424
21. Cancado ELR, Porta G. Autoimmune Hepatitis in South America. Dordrecht, Boston, London: Kluwer Academic Publishers; 2000:82-92
22. Kirk AP, Jain S, Pocock S, Thomas HC, Sherlock S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980;21:78-83
23. Geall MG, Schoenfield LJ, Summerskill WHJ. Classification and treatment of chronic active liver disease. Gastroenterology 1968;55(6):724-729
24. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972;63(5):820-833
25. Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997;25(3):541-547
26. Homberg JC, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 1987;7(6):1333-1339
27. Manns MP, Strassburg CP. Autoimmune hepatitis: clinical challenges. Gastroenterology 2001;120(6):1502-1517
28. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333(15):958-963
29. Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994;21(5):866-871
30. Newton JL, Burt AD, Park JB, Mathew J, Bassendine MF, James OF. Autoimmune hepatitis in older patients. Age Ageing 1997;26(6):441-444
31. Schramm C, Kanzler S, zum Büschenfelde KH, Galle PR, Lohse AW. Autoimmune hepatitis in the elderly. Am J Gastroenterol 2001;96(5):1587-1591
32. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006;43(3):532-538
33. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Signifi-cance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993;105(5):1502-1507
34. Al-Chalabi T, Boccato S, Portmann BC, McFarlane IG, Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006;45(4):575-583
35. Prelog M. Aging of the immune system: a risk factor for autoimmunity? Autoimmun Rev 2006;5(2):136-139
36. Talor E, Rose NR. Hypothesis: the aging paradox and autoimmune disease. Autoimmunity 1991;8(3):245-249
37. Thalén A, Brattsand R. Synthesis and anti-inflammatory properties of budesonide, a new non-halogenated glucocorticoid with high local activity. Arzneimittelforschung 1979; 29(11):1687-1690
38. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994;8(6):585-590
39. Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000;119(5):1312-1316
40. Wiegand J, Schüler A, Kanzler S, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005; 25(5):927-934
41. Rebollo Bernárdez J, Cifuentes Mimoso C, Piñar Moreno A, et al. Deflazacort for long-term maintenance of remission in type I autoimmune hepatitis. Rev Esp Enferm Dig 1999; 91(9):630-638
42. Strassburg CP, Bahr MJ, Becker T, Klempnauer J, Manns MP. [Progress in immunosuppression]. Chirurg 2008;79(2): 149-156
43. Alvarez F, Ciocca M, Cañero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999;30(2):222-227
44. Debray D, Maggiore G, Girardet JP, Mallet E, Bernard O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr 1999;135(1):111-114
45. Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong T-L. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999; 94(1):241-248
46. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002;35(1):7-13
47. Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90(5):771-776
48. Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004;38(9):805-809
49. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000;33(3):371-375
50. Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008;103(12):3063-3070
51. Kanzler S, Gerken G, Dienes HP, Meyer zum Büschenfelde K-H, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis- report of three cases. Z Gastroenterol 1997;35:571-578
52. Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990;11(1):12-15
53. Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999;30(6):1381-1386
54. Nakamura K, Yoneda M, Yokohama S, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis [see comments]. J Gastroenterol Hepatol 1998;13(5):490-495
55. Strassburg CP. [Autoimmune liver diseases and their overlap syndromes]. Praxis 2006;95:1363-1381
56. Rust C, Beuers U. Overlap syndromes among autoimmune liver diseases. World J Gastroenterol 2008;14(21):3368-3373
57. Ben-Ari Z, Dhillon AP, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology 1993;18(1):10-15
58. Angulo P, El-Amin O, Carpenter HA, Lindor KD. Development of autoimmune hepatitis in the setting of long-standing primary biliary cirrhosis. Am J Gastroenterol 2001;96(10):3021-3027
59. Colombato LA, Alvarez F, Côté J, Huet PM. Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis? Gastroenterology 1994; 107(6):1839-1843
60. Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998;28(2):296-301
61. Duclos-Vallée JC, Hadengue A, Ganne-Carrié N, Robin E, Degott C, Erlinger S. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Corticoresistance and effective treatment by cyclosporine A. Dig Dis Sci 1995;40(5):1069-1073
62. Al-Chalabi T, Portmann BC, Bernal W, McFarlane IG, Heneghan MA. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther 2008;28(2):209-220
63. Silveira MG, Talwalkar JA, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: longterm outcomes. Am J Gastroenterol 2007;102(6):1244-1250
64. Gossard AA, Lindor KD. Development of autoimmune hepatitis in primary biliary cirrhosis. Liver Int 2007;27(8): 1086-1090
65. Poupon R, Chazouilleres O, Corpechot C, Chrétien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006;44(1):85-90
66. Michieletti P, Wanless IR, Katz A, et al. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut 1994;35(2):260-265
67. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33(3): 544-553
68. Potthoff A, Deterding K, Trautwein C, et al. Steroid treatment for severe acute cryptogenic hepatitis. Z Gastroenterol 2007;45(1):15-19
69. Chazouillères O, Wendum D, Serfaty L, Rosmorduc O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2006;44(2):400-406
70. Strassburg CP, Becker T, Klempnauer J, Manns MP. [Liver transplantation: deciding between need and donor allocation]. Internist (Berl) 2004;45(11):1233-1245
71. Ahmed M, Mutimer D, Hathaway M, Hubscher S, McMaster P, Elias E. Liver transplantation for autoimmune hepatitis: a 12-year experience. Transplant Proc 1997;29(1-2):496
72. Neuberger J, Portmann B, Calne R, Williams R. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation 1984;37(4):363-365
73. Prados E, Cuervas-Mons V, de la Mata M, et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation 1998;66(12):1645-1650
74. Sanchez-Urdazpal L, Czaja AJ, van Holk B, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticoid-treated autoimmune chronic active hepatitis. Hepatology 1992;15:215-221
75. Tillmann HL, Jäckel E, Manns MP. Liver transplantation in autoimmune liver disease-selection of patients. Hepatogastroenterology 1999;46(30):3053-3059
76. Vogel A, Heinrich E, Bahr MJ, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant 2004;18(1):62-69
77. Strassburg CP, Manns MP. [Liver transplantation: indications and results]. Internist (Berl) 2009;50(5):550-560
78. Ratziu V, Samuel D, Sebagh M, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 1999;30(1):131-141
79. Schreuder TC, Hübscher SG, Neuberger J. Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far? Transpl Int 2009; 22(2):144-152
80. Devlin J, Donaldson P, Portmann B, Heaton N, Tan KC, Williams R. Recurrence of autoimmune hepatitis following liver transplantation. Liver Transpl Surg 1995;1(3):162-165
81. Manns MP, Bahr MJ. Recurrent autoimmune hepatitis after liver transplantation-when non-self becomes self. Hepatology 2000;32(4 Pt 1):868-870
82. Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999;68(2):253-256
83. Wright HL, Bou-Abboud CF, Hassanein T, et al. Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease. Transplantation 1992;53(1):136-139
84. Götz G, Neuhaus R, Bechstein WO, et al. Recurrence of autoimmune hepatitis after liver transplantation. Transplant Proc 1999;31(1-2):430-431
85. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006;12(12):1813-1824
86. Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neuberger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 2008;21(5):459-465
87. Campsen J, Zimmerman MA, Trotter JF, et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl 2008; 14(9):1281-1286
88. Kerkar N, Hadzić N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998;351(9100): 409-413
89. Salcedo M, Vaquero J, Bañares R, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002;35(2):349-356
90. Jones DE, James OF, Portmann B, Burt AD, Williams R, Hudson M. Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Hepatology 1999;30(1):53-57